Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT07776912
Recruiting Not applicable

Clinical Performance, Streptococcus Mutans Count, and Salivary pH for Cention-N, Zirconomer, and Resin-modified Glass Ionomer in Class I Restoration of Primary Molars

NCT07776912 · tracked via the Priya Life Science Egypt tracker
Sponsor
Galal Ali Mohamed Ebaid
Phase
Not applicable
Started
2025-08-01
Last updated
2026-08-20

Condition(s) studied

Streptococcus Mutans CountSalivary pHCention-NZirconomerResin-modified Glass IonomerClass I RestorationPrimary Molars

Investigational drug(s) / intervention(s)

Cention-NZirconomerResin-Modified Glass Ionomer

Cention-N: Class I cavity restoration using Cention-N self-curing resin-based dental restorative material according to the manufacturer's instructions.

Zirconomer: Class I cavity restoration using Zirconomer zirconia-reinforced glass ionomer restorative material according to the

Resin-Modified Glass Ionomer: Class I cavity restoration using Resin-Modified Glass Ionomer (RMGI) restorative material according to the manufacturer's instructions

Study summary

This study will evaluate the clinical performance, Streptococcus mutans count, and salivary pH for Cention-N, Zirconomer, and resin-modified glass ionomer in Class I restoration of primary molars.

Eligibility

Sex
ALL
Min age
4 Years
Max age
9 Years
Healthy volunteers
No
Inclusion Criteria: * Children aged between 4-9 years. * Children who have Class I lesions in both the maxillary and mandibular arches. * Primary molar teeth had class I carious lesions in occlusal pits and fissures; the gap between intercuspal surfaces should not be exceeded during cavity preparation. * Primary molars free of periapical pathosis. * Primary molars free root resorption. Exclusion Criteria: * Primary molars with preapical pathosis or hypersensitivity. * Primary molars with periodontal diseases or mobile molar tooth that indicated for extraction. * Nonfunctioning teeth with no opposing dentition; heavy occlusion or signs of severe attrition; and endodontically treated teeth.

Primary outcome measure(s)

  • Clinical Performance of Restorations — 6 months post-restoration
    Evaluation of the clinical performance of restorations using modified USPHS (FDI) criteria. It systematically grades how restorative materials (like composite resins, glass ionomers, and ceramics) perform in the mouth over time

Trial sites (1)

FacilityCityRegionStatus
Al-Azhar University (Faculty of Dentistry) Cairo Egypt Recruiting

Other trials for the same condition

Postoperative Bite Force After Bioflx and Zirconia Crowns in Children Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07776912 on ClinicalTrials.gov ↗ ← All trials in Egypt